Appeals court sides with Pfizer, Merck KGaA in $5bn suit

The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis (MS) drug patent, in a defeat for biotech company Biogen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

MSD secures victory before English court

20 October 2020 The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.

Asia-Pacific

Australian court issues mixed vaccine patent ruling

15 October 2020 In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.

Biotechnology

Biogen loses another battle over MS drug patent

21 September 2020 In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.

More on this story

Big Pharma

MSD secures victory before English court

20 October 2020 The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.

Asia-Pacific

Australian court issues mixed vaccine patent ruling

Biotechnology

Biogen loses another battle over MS drug patent

More on this story

Big Pharma

MSD secures victory before English court

20 October 2020 The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.

Asia-Pacific

Australian court issues mixed vaccine patent ruling

Biotechnology

Biogen loses another battle over MS drug patent